MET and non-small cell lung carcinoma: In this trial, the use of tepotinib in advanced NSCLC patients with MET alterations, including MET exon 14 skipping mutations and MET amplification, was correlated with an ORR of 46% (95% CI 36–57) based on an independent review, and a median PFS of 8.5 months (95% CI 6.7–11).